ENVISTA HOLDINGS Reports Fourth Quarter 2022 Earnings Results on February 8 2023.

Earnings Overview

On February 8 2023, ENVISTA HOLDINGS ($NYSE:NVST) reported their earnings results for the fourth quarter of fiscal year 2022, which concluded on December 31 2022. Total revenue for the quarter totaled USD 73.5 million, representing a decrease of 14.3% from the same period of the previous year. Net income, meanwhile, rose 1.4% year over year to USD 660.8 million.

Transcripts Simplified

Envista Holdings reported fourth quarter sales of $660.8 million, a 1.4% increase over the prior year. The sales were negatively impacted by 4%, due to foreign currency exchange rates, while acquisitions contributed 3.1% of growth in the quarter. Core sales growth was 2.3%, compared to the fourth quarter of 2021. The adjusted gross margin from continuing operations was 56.2%, a decrease of 90 basis points, compared to the prior year. The adjusted EBITDA margin for the quarter was 20.9%, which is 240 basis points higher than Q4 of 2021.

The fourth quarter adjusted EPS from continuing operations was $0.52, compared to $0.46 in the comparable period of the prior year, a 13% increase year-over-year. Core revenue in the Specialty Products and Technologies segment increased 4.5%, compared to the fourth quarter of 2021. Core sales in the Equipment and Consumables segment decreased 0.9%, compared to Q4 of 2021.

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Envista Holdings. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Envista Holdings. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Envista Holdings. More…

Key Ratios Snapshot

Some of the financial key ratios for Envista Holdings are shown below. More…

Share Price

Wednesday marked the opening of their stock, which opened at $41.0 and closed at $40.7, down by 2.0% from the last closing price of $41.5. The company’s share price has been volatile in the past few months as investors have been assessing their market performance and growth projections. ENVISTA HOLDINGS has been active in the market, announcing new partnerships and investments to strengthen their portfolio and increase returns.

In addition, they have also been making efforts to reduce costs and expand their customer base in order to remain competitive in their industry. Analysts are watching closely to see how ENVISTA HOLDINGS will fare in the coming quarters with their reported earnings. Investors will be looking for profits and improved performance in order to justify the current share price and the long-term outlook for the company. With the fourth quarter now in the bag, investors are sure to keep a close watch on ENVISTA HOLDINGS’ stock performance and financial statements to gain insight into their future prospects. Live Quote…

Analysis

GoodWhale has conducted an analysis of ENVISTA HOLDINGS‘s fundamentals and found that it is strong in assets, medium in profitability, and weak in dividend and growth. We assigned ENVISTA HOLDINGS a health score of 8/10, which indicates that it is capable of sustaining future operations in times of crisis. We classify ENVISTA HOLDINGS as an ‘elephant’, a type of company that is rich in assets after deducting off liabilities. Given ENVISTA HOLDINGS’s high asset and health scores, investors who are looking for a company with a strong financial standing and good potential for long-term growth may be interested in this company. Investors who are looking for short-term gains or higher dividend yields may want to look elsewhere. More…

Peers

Its main competitors are Medikit Co Ltd, Nihon Kohden Corp, and Fukuda Denshi Co Ltd. Envista has a strong market presence in the US, Europe, and Asia Pacific.

– Medikit Co Ltd ($TSE:7749)

As of 2022, Medikit Co Ltd has a market cap of 41.17B and a Return on Equity of 6.14%. The company produces and sells medical equipment and supplies. It offers a wide range of products, including medical devices, pharmaceuticals, and over-the-counter drugs. Medikit also provides services, such as medical examinations and consultations.

– Nihon Kohden Corp ($TSE:6849)

Nihon Kohden is a Japanese manufacturer of medical equipment, with a particular focus on patient monitoring systems. The company has a market cap of 278.79B as of 2022 and a return on equity of 13.19%. Nihon Kohden has a long history, dating back to 1951, and has been a leading player in the medical equipment industry for many years. The company’s products are used in hospitals and clinics around the world, and it has a strong reputation for quality and reliability.

– Fukuda Denshi Co Ltd ($TSE:6960)

Fukuda Denshi Co Ltd is a Japanese company that manufactures and sells medical equipment. The company has a market cap of 138.83B as of 2022 and a Return on Equity of 9.95%. Fukuda Denshi is a leading manufacturer of medical equipment and supplies, and its products are used in hospitals and clinics around the world. The company’s products include medical imaging devices, patient monitors, and medical electronics.

Summary

Investors should take note of the Envista Holdings earnings report for the fourth quarter of FY 2022. While the company’s total revenue was down 14.3% compared to the same period last year, net income rose 1.4%. This indicates the company is making cost-saving measures and increasing its profitability.

Although investors may have some concerns about the decline in revenue, the higher net income provides some upside potential for future earnings. It also serves as a positive signal for the company’s overall performance and outlook.